Amicus Therapeutics to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

CRANBURY, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on Wednesday, September 27, 2017 at 1:00 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at, and will be archived for 90 days.  

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.


Amicus Therapeutics
Sara Pellegrino, IRC
Senior Director, Investor Relations
(609) 662-5044

W2O Group
Jennifer Paganelli
(347) 658-8290


Primary Logo

Source: Amicus Therapeutics, Inc

News Provided by Acquire Media